We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.


Genentech is committed to supporting programs that help grow and strengthen the diversity of the healthcare and biomedical research workforce, in order to ensure that all patients, including those from communities of color and other underrepresented groups, can receive relevant treatments and high quality care.

Important Notice

Genentech is committed to supporting our existing grantees during the evolving coronavirus (COVID-19) pandemic. We understand that grantees will have their own challenges in adapting to rapidly changing events, and we will work to accommodate needs for the programs funded by Genentech.

If you are an existing grantee, please contact your Genentech representative with questions or to let us know if your program or event will be cancelled or postponed. If you are unsure of who to contact, please email [email protected] and we will direct you to the appropriate person.

For more information on Genentech’s relief and recovery efforts during the COVID-19 pandemic, please visit our COVID-19 response page.

Fellowships are for grants to independent professional organizations, independent charitable organizations, or other eligible institutions, where the funds are used to support advanced study by clinical and research professionals at an accredited university or teaching institution. To reflect Genentech’s commitment to building a diverse and inclusive workforce, we prioritize requests that support the career development, persistence and retention of students and professionals who are members of gender, racial and/or ethnic groups that are historically underrepresented in academic medicine and biomedical research.

Decision Making

Requests must be submitted at least 90 days prior to the project/program start date. Decisions are made on a case-by-case basis; Genentech will be in touch regarding your proposal and you will receive a decision prior to the project/program start date.

Letter of Agreement (LOA)

All grants must abide by the terms in the Genentech Letter of Agreement (LOA), which is issued to an authorized signer of your organization once the application is approved. You must agree to the terms of the LOA before any funding is issued. If you have any questions on the agreement terms, please contact us at (877) 313-5778.

Note: The funding application site does not support IE8 or earlier

*We are no longer accepting unsolicited grant submissions for the 2021 funding year.

*We are no longer accepting unsolicited grant submissions for the 2021 funding year.